Cyclosporine is an immunosuppressant that blocks T-cell activation by preventing IL-2 transcription (FA2020 p120)

Even without remembering the mechanism of cyclosporine, the answer could be inferred as most medications used after kidney transplant (cyclosporine, tacrolimus, sirolimus, basiliximab) block T-cell activation. This mechanism MAKES LOGICAL SENSE because T-cells are the primary mediators of acute rejection, which is what we are trying to prevent directly after a kidney transplant.